Legend Biotech Corporation
NASDAQLegend Biotech is ending the week with a 42% single-day surge and a month that has rewritten the stock's positioning narrative entirely. The catalyst is concrete. Legend presented initial Phase 1 data for LB2501 — its in vivo CAR-T candidate — in non-Hodgkin lymphoma at EHA 2026, catching the market by surprise. For a name whose entire bull case rests on CAR-T innovation beyond…
Snapshot as of 3 Jun 2026
Legend Biotech is ending the week with a 42% single-day surge and a month that has rewritten the stock's positioning narrative entirely. The catalyst is concrete. Legend presented initial Phase 1 data for LB2501 — its…
Legend Biotech enters the post-earnings week with shorts in rapid retreat and the Street scrambling to reprice a CARVYKTI royalty story that just posted its best quarterly revenue growth in two years. The catalyst is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LEGN — free to start on ORTEX.
Sign up for free →Open LEGN on ORTEX